1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Now Available: Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines

New Pharmaceuticals market report from Datamonitor: "Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines"

 
PRLog - Dec. 18, 2010 - Over the next decade, Pfizer's Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad MenB vaccine could achieve blockbuster status.

Features and benefits
In-depth analysis of market dynamics for pneumo-and meningococcal vaccines across US, 5EU and Japan, supported by insights of key opinion leaders
Population-based 10-year sales forecasts for currently available brands and late-stage pipeline vaccines in the US and 5EU.
Epidemiology section discussing key population trends and epidemiological features of pneumo- and meningococcal disease in the seven major markets
Thorough assessments of key marketed vaccines and late stage pipeline products.
Highlights
Datamonitor anticipates the launch of Pfizer's Prevnar 13 for adults in 2011 and expects the vaccine to quickly replace Merck & Co's Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU markets.

Sales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a meningococcal B vaccine.

Pneumo- and meningococcal vaccines continue to offer great commercial opportunities due to changing disease epidemiology and extension of age indications. Novartis' 4CMenB is the most promising pipeline vaccine and expected to quickly reach blockbuster status with possible sales of almost $3 billion in the US and the five major European ma

Your key questions answered
Identify the market dynamics of pneumo- and meningococcal vaccines, success factors for leading brands and the potential of late stage pipeline
Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019.
Understand epidemiological trends of pneumo-and meningococcal disease across the seven major markets and their impact on vaccination recommendations

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/101503_pipeline_and_commercial...

Partial Table of Contents:

TABLE OF CONTENTS
OVERVIEW 1
Catalyst 1
Summary 1
About Datamonitor healthcare 2
About the Vaccines & Infectious Diseases Pharmaceutical Analysis Team 2
EXECUTIVE SUMMARY 3
Strategic scoping and focus 3
Datamonitor insight into the pneumococcal and meningococcal vaccines market 3
Related reports 4
Upcoming related reports 4
PNEUMOCOCCAL VACCINES 19
Summary 19
Pneumococcal disease background 20
Epidemiological context 21
Introduction 21
Key points 21
Disease definition and diagnosis criteria 21
Surveillance of invasive pneumococcal disease 22
Impact of vaccines 23
Serotype replacement 23
Market-specific epidemiology 25
US 30
Japan 31
France 31
Germany 32
Italy 32
Spain 33
UK 34
Epidemiologic forecasting of IPD vaccine-eligible population 35
US 36
France 38
Germany 38
Italy 38
Spain 38
UK 38
Results 39
Discussion 42
Vaccination recommendations 42
Infants 43
Launch of first conjugate vaccine Prevnar 7 from 2000 onwards allowed routine vaccination of infants 43
Prevnar 13 is set to entirely replace Prevnar 7 in infants 43
US 45
Japan 46
France 46
Germany 47
Italy 47
Spain 49
UK 50
Adults and elderly 50
Prevnar 13 is likely to replace Pneumovax 23 in primary vaccination of adults and elderly 50
US 52
Japan 53
France 53
Germany 53
Italy 53
Spain 53
UK 53
Vaccination coverage 54
Infants 54
US 55
Japan 56
France 56
Germany 57
Italy 57
Spain 58
UK 58
Adults and elderly 58
US 58
Japan 60
France 60
Germany 61
Italy 61
Spain 61
UK 61
Overview of the competitive landscape 63
Four vaccines are marketed for the prevention of infection with S. pneumoniae 63
There are different strategies to boost the primary immune response of conjugate vaccines 64
Key companies and strategies 66
Pfizer - clear dominance through Prevnar franchise 67
Merck & Co - increasing pressure for Pneumovax 68
GlaxoSmithKline - emerging markets as an expansion strategy for Synflorix 68
Deals with GAVI provide an opportunity to penetrate developing markets 69
Access to potential future markets is a key incentive for pharmaceutical companies 72
WHO request for additional trials on Synflorix two-dose presentation expected to delay vaccine allocation 72
Unmet needs 73
Marketed and pipeline vaccines 74
Pneumovax (23-valent pneumococcal polysaccharide vaccine, Merck & Co) 74
Overview 74
Vaccine profile 75
Product positioning 75
SWOT analysis 77
Satisfaction of unmet needs 81
Forecast to 2019 81
Prevnar 7 (7-valent pneumococcal conjugate vaccine, Pfizer) 82
Overview 82
Vaccine profile 85
Drug positioning 85
SWOT analysis 86
Satisfaction of unmet needs 89
Forecast to 2019 90
Prevnar 13 (13-valent pneumococcal conjugate vaccine, Pfizer) 90
Overview 90
Vaccine profile 92
Clinical trial data 92
Drug positioning 103
SWOT analysis 103
Satisfaction of unmet needs 108
Forecast to 2019 108
Synflorix (10-valent pneumococcal conjugate vaccine, GlaxoSmithKline) 110
Overview 110
Vaccine profile 111
Clinical trial data 111

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1015...

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment.  View more research from Datamonitor at http://www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

--- End ---

Click to Share

Contact Email:
***@fastmr.com Email Verified
Source:Fast Market Research
Phone:1.800.844.8156
Zip:01267
State/Province:Massachusetts - United States
Industry:Medical, Research, Biotech
Tags:vaccine, meningococcal, pneumococcal, prevnar, disease, conjugate, drug, menacwy, pipeline, menb
Shortcut:prlog.org/11160005
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share